Collegium Pharmaceutical
COLL
250 hedge funds and large institutions have $1.49B invested in Collegium Pharmaceutical in 2024 Q3 according to their latest regulatory filings, with 40 funds opening new positions, 102 increasing their positions, 77 reducing their positions, and 19 closing their positions.
215% more call options, than puts
Call options by funds: $2.65M | Put options by funds: $842K
111% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 19
32% more repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 77
9% more funds holding
Funds holding: 229 → 250 (+21)
5.71% more ownership
Funds ownership: 114.13% → 119.84% (+5.7%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
24% less capital inflows, than outflows
Capital inflows: $120M | Capital outflows: $158M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$8.19M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$7.7M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$7.28M |
| 4 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$6.37M |
| 5 |
Emerald Advisers
Leola,
Pennsylvania
|
+$6.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Rubric Capital Management (New York)
New York
|
-$38.6M |
| 2 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$29.2M |
| 3 |
Jefferies Financial Group
New York
|
-$10.8M |
| 4 |
BlackRock
New York
|
-$9.8M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$7.85M |
COLL Hedge Fund Activity: Q3 2024 in Review
250 of the 6,987 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q3 2024, worth a combined $1.49B — up 17% from $1.28B a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new COLL positions and 19 closed out — a net gain of 21 holders — while 102 added to existing stakes and 77 trimmed.
The largest buyer was Goldman Sachs, adding an estimated $8.19M. The largest seller was Rubric Capital Management (New York), cutting an estimated $38.6M.
- 250 institutional investors held Collegium Pharmaceutical (COLL) as of Q3 2024, up from 229 in Q2 2024.
- Funds reported $1.49B of Collegium Pharmaceutical stock for Q3 2024, up 17% quarter-over-quarter.
- 40 funds opened new Collegium Pharmaceutical positions in Q3 2024 and 19 closed out, a net change of +21 holders.
- The largest Collegium Pharmaceutical buyer in Q3 2024 was Goldman Sachs, an estimated $8.19M added.
- The largest Collegium Pharmaceutical seller in Q3 2024 was Rubric Capital Management (New York), an estimated $38.6M sold.
Based on aggregated 13F filings for Q3 2024.